

Your Abstract Submission Has Been Received

Print this page

You have submitted the following abstract to 2021 Annual Meeting of the Consortium of Multiple Sclerosis Centers. Receipt of this notice does not guarantee that your submission was complete or free of errors.

Development and Usability Testing of a Patient-Based Digital Tool to Detect Early Signs of Changes in Multiple Sclerosis Symptoms and Progression: Your MS Questionnaire

Tjalf Ziemssen, MD, PhD¹, Enrique Alvarez, MD, PhD², Virender Bhan, MD³, Jason Burton, MBBS⁴, Olaf Hoffmann, PD Dr. med.⁵, Celia Oreja-Guevara, MD⁶, René Robles-Cedeño, MD, PhD⁷, Maria Trojano, MD⁸, Patrick Vermersch, MD, PhD⁹, Salvatore Napoli, MD¹⁰, Augusto Miravalle, MD¹¹, Yan Xu, MD, PhD¹², Jo Vandercappellen, PhD, MBA¹³, Mudeer Khwaja, BSc¹³, Mark Marchaterre, IT BS¹⁴, Bianca Stadler, PhD¹⁵, Thomas Hach, MD¹³ and Gavin Giovannoni, MD, PhD¹⁶, (1)Department of Neurology, University Clinic Carl-Gustav Carus, Dresden, Germany, (2)University of Colorado School of Medicine, Aurora, CO, (3)University of British Columbia, Vancouver, BC, Canada, (4)Centre for Neuromuscular and Neurological Disorders, Western Australian Neuroscience Research Institute, The University of Western Australia, Perth, Australia, (5)Department of Neurology, Alexianer St. Josefs Hospital, Potsdam, Germany, (6)Department of Neurology, University Hospital San Carlos, Idissc, Madrid, Spain, (7)Neuroimmunology and Multiple Sclerosis Unit, Girona, Spain, (8)University of Bari, Bari, Italy, (9)Department of Neurology, University of Lille, CHU Lille, LIRIC-U995, FHU-Imminent, Lille, France, (10)Partners, Multiple Sclerosis Center, and Center for Neurological Imaging, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, (11)Department of Neurology, University of Colorado, Denver, CO, (12)Multiple Sclerosis Center, Department of Neurology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China, (13)Novartis Pharma AG, Basel, Switzerland, (14)Novartis Services Inc., East Hanover, East Hanover, NJ, (15)Novartis Pharma GmbH, NÜRNBERG, Germany, (16)Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom

Abstract Text:

Background: The validated physician-completed MSProDiscuss™ tool facilitates physician-patient interaction in evaluating early signs of disease progression and the risk of transition from RRMS to SPMS. While evaluating MSProDiscuss, development of a patient-completed tool was a commonly received suggestion to monitor experiences of people with multiple sclerosis (pwMS) over time and facilitate discussions with healthcare professionals (HCPs).

Objectives: To develop a patient-based tool, *Your MS Questionnaire*, completed by pwMS, and evaluate its usability to help both pwMS and HCPs understand changes in MS-symptoms, disease progression, and their impact on daily activities.

Methods: *Your MS Questionnaire* is derived from MSProDiscuss, using input from pwMS, patient organizations and HCPs to include feedback from a broad range of the RRMS/SPMS patients. By means of 15 questions, it captures the individual perception of pwMS regarding changes in MS symptoms, disability progression and impact on daily living over the past 6 months. For testing of the questionnaire, two surveys (15 questions each) are being conducted among the treating neurologists initially after every consultation to understand patient-details, patient-satisfaction, HCP-satisfaction, and usability of MSProDiscuss, and again after up to 40 consultations (minimum 10 consultations required) capturing in-depth feedback on usefulness, integration in daily clinical routine in addition to MSProDiscuss, and improvement areas. PwMS were given the choice of electronic or paper version of the questionnaire.

Results: Usability testing of *Your MS Questionnaire* is currently ongoing across eight countries including the US, UK, Germany, Spain, Italy, Canada, Australia and China, permitting assessment of different aspects of the tool's usability. Results will be presented at the meeting.

Conclusions: *Your MS Questionnaire* will facilitate the collection of real-world feedback from pwMS to help neurologists manage MS-disease activity and symptoms in daily-life. When completed before consultations, it may benefit pwMS and physicians through a better-structured conversation, including potential uses in telemedicine.

Title:

Development and Usability Testing of a Patient-Based Digital Tool to Detect Early Signs of Changes in Multiple Sclerosis Symptoms and Progression: Your MS Questionnaire

Submitter's E-mail Address:

gillipsie.minhas@novartis.com

Preferred Presentation Format:

Platform/Oral

Category:

Quality of life and outcomes

Would you give CMSC and International Journal of MS Care the first preference to any article that is submitted for publication based on this abstract presentation?:

No

Category: Quality of life and outcomes

Keywords:

Comprehensive care and MS and Management of activities of daily living in MS

First Presenting Author***Presenting Author***

Tjalf Ziemssen, MD, PhD

Email: Tjalf.Ziemssen@uniklinikum-dresden.de -- Will not be published

Department of Neurology, University Clinic Carl-Gustav Carus
Dresden
Germany

[Click to view Conflict of Interest Disclosure](#)

Second Author

Enrique Alvarez, MD, PhD

Email: ENRIQUE.ALVAREZ@UCDENVER.EDU -- Will not be published

University of Colorado School of Medicine
Aurora CO
USA

[Click to view Conflict of Interest Disclosure](#)

Third Author

Virender Bhan, MD

Email: virenderb1@gmail.com -- Will not be published

University of British Columbia
Vancouver BC
Canada

[Click to view Conflict of Interest Disclosure](#)

Fourth Author

Jason Burton, MBBS

Email: jargonauts@gmail.com -- Will not be published

Centre for Neuromuscular and Neurological Disorders, Western Australian Neuroscience
Research Institute, The University of Western Australia
Perth
Australia

[Click to view Conflict of Interest Disclosure](#)

Fifth Author

Olaf Hoffmann, PD Dr. med.

Email: o.hoffmann@alexianer.de -- Will not be published

Department of Neurology, Alexianer St. Josefs Hospital
Potsdam
Germany

[Click to view Conflict of Interest Disclosure](#)

Sixth Author

Celia Oreja-Guevara, MD

Email: orejacbn@gmail.com -- Will not be published

Department of Neurology, University Hospital San Carlos, Idissc
Madrid
Spain

[Click to view Conflict of Interest Disclosure](#)

Seventh Author

René Robles-Cedeño, MD, PhD

Email: rrobles.girona.ics@gencat.cat -- Will not be published

Neuroimmunology and Multiple Sclerosis Unit
Girona
Spain

[Click to view Conflict of Interest Disclosure](#)

Eighth Author

Maria Trojano, MD

Email: maria.trojano@uniba.it -- Will not be published

University of Bari
Bari

Italy

[Click to view Conflict of Interest Disclosure](#)

Ninth Author

Patrick Vermersch, MD, PhD

Email: patrick.vermersch@univ-lille.fr -- Will not be published

Department of Neurology, University of Lille, CHU Lille, LIRIC-U995, FHU-Imminent
Lille
France

[Click to view Conflict of Interest Disclosure](#)

Tenth Author

Salvatore Napoli, MD

Email: snapoli@myneurodr.com -- Will not be published

Partners, Multiple Sclerosis Center, and Center for Neurological Imaging, Department of
Neurology, Brigham and Women's Hospital, Harvard Medical School
Boston MA
USA

[Click to view Conflict of Interest Disclosure](#)

Eleventh Author

Augusto Miravalle, MD

Email: amiravalle@yahoo.com -- Will not be published

Alternate Email: amiravalle@yahoo.com -- Will not be published

Department of Neurology, University of Colorado
Denver CO
USA

[Click to view Conflict of Interest Disclosure](#)

Twelfth Author

Yan Xu, MD, PhD

Email: xuyanpumch@hotmail.com -- Will not be published

Multiple Sclerosis Center, Department of Neurology, Peking Union Medical College
Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences
Beijing
China

[Click to view Conflict of Interest Disclosure](#)

Thirteenth Author

Jo Vandercappellen, PhD, MBA

Email: jo.vandercappellen@novartis.com -- Will not be published

Novartis Pharma AG
Basel
Switzerland

[Click to view Conflict of Interest Disclosure](#)

Fourteenth Author

Mudeer Khwaja, BSc

Email: mudeer.khwaja@novartis.com -- Will not be published

Novartis Pharma AG
Basel
Switzerland

[Click to view Conflict of Interest Disclosure](#)

Fifteenth Author

Mark Marchaterre, IT BS

Email: mark.marchaterre@novartis.com -- Will not be published

Novartis Services Inc., East Hanover
East Hanover NJ
USA

[Click to view Conflict of Interest Disclosure](#)

Sixteenth Author

Bianca Stadler, PhD

Email: bianca.stadler@novartis.com -- Will not be published

Novartis Pharma GmbH
NÜRNBERG
Germany

[Click to view Conflict of Interest Disclosure](#)

Seventeenth Author

Thomas Hach, MD

Email: thomas.hach@novartis.com -- Will not be published

Novartis Pharma AG
Basel
Switzerland

[Click to view Conflict of Interest Disclosure](#)

Eighteenth Author

Gavin Giovannoni, MD, PhD

Email: g.giovannoni@qmul.ac.uk -- Will not be published

Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary
University of London

London
United Kingdom

[Click to view Conflict of Interest Disclosure](#)

First Contact

Gillipsie Minhas, PhD
Email: gillipsie.minhas@novartis.com -- Will not be published

Novartis Healthcare Private Limited
Hyderabad
India

Second Contact

Suzannah Ryan, PhD
Email: suzannah.ryan_ext@novartis.com -- Will not be published

Novartis Pharma AG
Basel
Switzerland

If necessary, you can make changes to your abstract submission

To access your submission in the future, use the direct link to your abstract submission from one of the automatic confirmation emails that were sent to you during the submission.

Or point your browser to [/cmssc/remindercgi](https://cmssc/remindercgi) to have that URL mailed to you again. Your username/password are 7258/.

Any changes that you make will be reflected instantly in what is seen by the reviewers. You DO NOT need to go through all of the submission steps in order to change one thing. If you want to change the title, for example, just click "Title" in the abstract control panel and submit the new title.

When you have completed your submission, you may close this browser window.

[Tell us what you think of the abstract submission process](#)

[Home Page](#)